ATE441710T1 - Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen - Google Patents

Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen

Info

Publication number
ATE441710T1
ATE441710T1 AT04706034T AT04706034T ATE441710T1 AT E441710 T1 ATE441710 T1 AT E441710T1 AT 04706034 T AT04706034 T AT 04706034T AT 04706034 T AT04706034 T AT 04706034T AT E441710 T1 ATE441710 T1 AT E441710T1
Authority
AT
Austria
Prior art keywords
hif
inhibit
expression level
antisense oligonucleotides
cell lines
Prior art date
Application number
AT04706034T
Other languages
English (en)
Inventor
Heejeong Yoon
Lingjun Mao
Young Lee
Chang-Ho Ahn
Xiaoming Jiang
Original Assignee
Rexahn Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Corp filed Critical Rexahn Corp
Priority claimed from PCT/US2004/002344 external-priority patent/WO2004066949A2/en
Application granted granted Critical
Publication of ATE441710T1 publication Critical patent/ATE441710T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04706034T 2003-01-31 2004-01-28 Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen ATE441710T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44436703P 2003-01-31 2003-01-31
PCT/US2004/002344 WO2004066949A2 (en) 2003-01-28 2004-01-28 Antisense oligonucleotides that inhibit expression of hif-1

Publications (1)

Publication Number Publication Date
ATE441710T1 true ATE441710T1 (de) 2009-09-15

Family

ID=35261932

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04706034T ATE441710T1 (de) 2003-01-31 2004-01-28 Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen

Country Status (9)

Country Link
US (1) US7205283B2 (de)
EP (1) EP1601325B1 (de)
KR (1) KR101069521B1 (de)
CN (1) CN100471862C (de)
AT (1) ATE441710T1 (de)
BR (1) BRPI0407070A (de)
CA (1) CA2513398C (de)
DE (1) DE602004022921D1 (de)
ES (1) ES2333794T3 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
WO2005032486A2 (en) * 2003-10-02 2005-04-14 Duke University A NOVEL SIRNA-BASED APPROACH TO TARGET THE HIF-α FACTOR FOR GENE THERAPY
WO2006026485A2 (en) * 2004-08-25 2006-03-09 Isis Pharmaceuticals, Inc. Modulation of hif1-beta expression
US20100074897A1 (en) * 2006-12-01 2010-03-25 University Of Utah Research Foundation Methods and Compositions related to HIF-1 alpha
US20080318241A1 (en) * 2007-06-18 2008-12-25 The Regents Of The University Of Michigan Methods and Systems for Detecting Antiangiogenesis
HRP20170737T1 (hr) 2010-04-29 2017-07-28 Ionis Pharmaceuticals, Inc. Modulacija ekspresije transtiretina
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
AU2013266238B2 (en) 2012-05-23 2017-07-27 The Ohio State University Lipid-coated albumin nanoparticle compositions and methods of making and method of using the same
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
EP1189611B1 (de) * 1999-06-14 2006-05-03 Cancer Research Technology Limited Krebstherapie
US7105656B2 (en) * 2000-10-26 2006-09-12 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
SI2264172T1 (sl) * 2002-04-05 2017-12-29 Roche Innovation Center Copenhagen A/S Oligomerne spojine za modulacijo izražanja HIF-1alfa
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression

Also Published As

Publication number Publication date
KR101069521B1 (ko) 2011-09-30
EP1601325B1 (de) 2009-09-02
US7205283B2 (en) 2007-04-17
EP1601325A4 (de) 2008-02-20
ES2333794T3 (es) 2010-03-01
CN100471862C (zh) 2009-03-25
BRPI0407070A (pt) 2006-01-24
KR20050103476A (ko) 2005-10-31
US20040152655A1 (en) 2004-08-05
EP1601325A2 (de) 2005-12-07
CA2513398A1 (en) 2004-08-12
CA2513398C (en) 2013-09-10
CN1809583A (zh) 2006-07-26
DE602004022921D1 (de) 2009-10-15

Similar Documents

Publication Publication Date Title
MXPA03003151A (es) Metodos de diagnostico de cancer de prostata, composiciones y metodos para seleccionar moduladores de cancer de prostata.
TW200610756A (en) Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
BRPI0518228A (pt) inibidores de cinesina mitótica e métodos de uso destes
EP1290005A4 (de) Vegf-modulierte gene und verfahren, die diese verwenden
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
DE602005017753D1 (de) Mittel für die transdermale verabreichung von nikotin
EP1601325A4 (de) Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen
WO2004016215A3 (en) Use of antisense oligonucleotides to inhibit the expression of akt-1
CA108704S (en) Cutting insert structure
PL1753512T3 (pl) Tetrahydropirydotiofeny
DE60044503D1 (de) Die zellvermehrung hemmendes protein, polynukleotid, antisens-polynukleotid und zellvermehrungshemmer, krebsdiagnostik, krebsheilmittel und zusammensetzungen zur gentherapie
ITTO20000355A0 (it) Trattamento superficiale per inserto in carburo di tungsteno.
WO2004066949A8 (en) Antisense oligonucleotides that inhibit expression of hif-1
PL1713438T3 (pl) Mydło lecznicze
TW200500065A (en) Antiarthritic combinations
ITMI20032037A1 (it) Supporto del cruscotto.
EP1707630A4 (de) Antisense-oligonukleotid mit antikrebsaktivität
UY29136A1 (es) Uso de epotilonas en el tratamiento de metastasis osea
ES1053847Y (es) Perfeccionamientos introducidos en carteras.
ITPD20020161A1 (it) Macchina degerminatrice, in particolare per la degerminazione di cereali.
ES1053837Y (es) Mampara para ducha o bañera, mejorada.
CA102792S (en) Dispenser pump for medication
ITRM20020328A1 (it) Matrici per dnaser.
ES2355499T8 (es) Nitrosofenoles y c-nitrosoanilinas como inhibidores de polimerización.
IT1318702B1 (it) Metodo per la determinazione quantitativa del gene smn1.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties